4.5 Article

A novel linear neutralizing epitope of hepatitis E virus

Journal

VACCINE
Volume 33, Issue 30, Pages 3504-3511

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2015.05.065

Keywords

Hepatitis E virus; Linear epitope; Nonimmunodominant; Vaccine; Neutralization

Funding

  1. Chinese National High-tech R&D Program (863 program) [2011AA02A101]
  2. Xiamen Science and Technology Platform Project [3502Z20131001]
  3. Xiamen Science and Technology Plan Project [3502Z201410045]

Ask authors/readers for more resources

Hepatitis E virus (HEV) is a serious public health problem that causes acute hepatitis in humans and is primarily transmitted through fecal and oral routes. The major anti-HEV antibody responses are against conformational epitopes located in a.a. 459-606 of HEV pORF2. All reported neutralization epitopes are present on the dimer domain constructed by this peptide. While looking for a neutralizing monoclonal antibody (MAb)-recognized linear epitope, we found a novel neutralizing linear epitope (L2) located in a.a. 423-437 of pORF2. Moreover, epitope L2 is proved non-immunodominant in the HEV-infection process. Using the hepatitis B virus core protein (HBc) as a carrier to display this novel linear epitope, we show herein that this epitope could induce a neutralizing antibody response against HEV in mice and could protect rhesus monkeys from HEV infection. Collectively, our results showed a novel non-immunodominant linear neutralizing epitope of hepatitis E virus, which provided additional insight of HEV vaccine. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available